Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that haploinsufficiency of SPINK5 can lead to Netherton syndrome when a single null mutation combines with homozygous G1258A polymorphisms, suggesting it acts as a genuine mutation affecting LEKTI function.

This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

This study observed that in pemphigus vulgaris patients, hair loss and alopecic patches may result from anti-desmoglein autoantibody-mediated acantholysis and inflammatory changes, leading to non-scarring alopecia with potential for regrowth after treatment.

This study reports a novel TRbeta gene mutation associated with resistance to thyroid hormone syndrome, which may contribute to various forms of alopecia in the affected family members.

This review discusses current treatments and management strategies for hidradenitis suppurativa, noting the mixed effectiveness of various therapies, including surgery, antibiotics, and hormonal treatments, but reports no new clinical findings.

In this review, researchers detail how immunosenescence and chronic neuroinflammation contribute to Parkinson's disease progression, exploring potential therapeutic strategies targeting this axis, such as senolytic agents and immune rejuvenation, while highlighting associated challenges and future research needs.

Terbinafine is the most effective medicine for fungal nail infections, especially for diabetics and those with weak immune systems.

This review explores various theories of colorectal cancer stem cell biology and highlights the need for better identification and targeting of these cells to advance treatment strategies, but reports no new clinical findings.

This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.

This study reports the first documentation of mural, mucinotic, isthmus folliculitis alopecia in Norwegian puffin dogs, noting that ciclosporin treatment led to remission while other treatments were less effective.

This article reviews the endocrine changes in anorexia nervosa and bulimia nervosa, highlighting hypoleptinemia as a potential mediator, but does not present any new clinical results.

In this study, researchers observed that twins with a novel de novo nonsense variant in HRAS exhibited distinctive features, including neuropsychiatric symptoms, potentially indicating a wider clinical spectrum for conditions known as RASopathies.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

This study reviewed a corticosteroid treatment regimen for a 52-year-old woman with extensive alopecia areata, showing significant hair regrowth and sustained remission over 12 months, suggesting oral mini-pulse therapy as a viable alternative for those ineligible for JAK inhibitors.

In this study, a nanoparticle system codelivering diphenylcyclopropenone and rapamycin successfully induced immune tolerance and promoted hair regrowth in a mouse model of alopecia areata, offering a promising new therapeutic strategy for this autoimmune condition.

This study found that alopecia areata is associated with distinct systemic and tissue immune signatures, with macrophages implicated as contributors to hair loss, suggesting potential therapeutic targeting of macrophage activity.

In this study, researchers did not find any genome-wide significant genetic signals linked to comorbid chronic inflammatory disorders in patients with alopecia areata, but exploratory analysis suggested potential associations worth further study.

This review article discusses recent advances in stem cell-based therapies for Alopecia Areata, noting preliminary clinical trials show significant hair regrowth, but emphasizes the need for thorough evaluation of long-term safety and efficacy.

This study found that innate lymphoid cells-type 1 (ILC1) can induce alopecia areata by disrupting hair follicle immune privilege without the involvement of classical CD8+ T cells.

This review suggests that melasma may be a photoaging skin disorder affecting genetically predisposed individuals, which could significantly influence its treatment and prevention strategies.

This review covers the diverse cutaneous and systemic presentations of sarcoidosis in patients with skin of color, emphasizing the importance of early recognition to improve outcomes despite a generally poorer prognosis compared to Caucasians.

This review of seborrheic dermatitis highlights the role of complex immunoinflammatory processes in its pathogenesis and discusses emerging treatments, such as PDE4 inhibitors, JAK inhibitors, and microbiome-targeted therapies, which may benefit patients with severe or treatment-resistant forms, according to the authors.

This research concludes that adipose mesenchymal stem cells are uniquely evolved to manage skin inflammation in newborns and their released molecules are the safest and most effective for skin therapeutics.

This review discusses progress in targeted therapies for vitiligo, focusing on Janus kinase inhibitors and the potential of mesenchymal stem cells, but reports no new clinical results.

This systematic review suggests that platelet-rich plasma may significantly improve symptoms in oral lichen planus with effects comparable to corticosteroids, although more research is needed to confirm these findings.

This study found that a combination therapy of oral corticosteroid and oral PUVA led to scalp hair regrowth in patients with intractable alopecia totalis and universalis within two months.

This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.

Premature graying of hair is mainly caused by genetics, stress, and environment, with potential treatments being explored.